SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Walter Morton who wrote (2472)9/9/1999 6:51:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
CIST claims to have patents on PAI-2 and considers Biotech Australia a business partner. Yet Biotech Australia claims to have patents on PAI-2 also. I'm going to do a little more research on this to see where CIST's patents stop and Biotech Australia's patents begins. In other words, will CIST make any money on this new ulcer medication?

The email address at Genome securities does not work and Cistron will not respond to my emails. So, this may take some time to figure out.



To: Walter Morton who wrote (2472)9/10/1999 11:39:00 PM
From: Walter Morton  Respond to of 2742
 
<<Biotech Australia is currently on the market, and we are looking for investors, as well as for pharmaceutical partners for later stage development and marketing of PAI-2.>>

Message 11204892

I wonder if Genome Securities and CIST know about this.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News